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An increased prevalence of type 2 di-abetes and impaired glucose toler-ance has been consistently found in
liver cirrhosis from any cause (1–3). Less
clear is whether hepatitis C virus (HCV)
infection is associated with type 2 diabe-
tes in the absence of cirrhosis. Several re-
ports have claimed a specific association
between HCV infection and type 2 diabe-
tes, but in most instances, patients were a
mixture of cases with cirrhosis and hepa-
titis (4 – 6). Two clinic-based studies
found an excess of type 2 diabetes in non-
cirrhotic HCV (NC-HCV) patients
compared with patients with chronic
hepatitis of other origin (7–9), but an-
other large study could not detect it (10).
Furthermore, one clinic-based small
study found a specific association with
type 2 diabetes in NC-HCV patients
(11) compared with a general population
sample.
The aim of this study was to establish
the prevalence and clinical phenotype of
type 2 diabetes in a large series of NC-
HCV patients. A sample of the general
population or patients with hepatitis B vi-
rus (HBV)-related noncirrhotic chronic
hepatitis (NC-HBV) was used as control
subjects.
RESEARCH DESIGN AND
METHODS— From January 1995 to
December 2001, 564 NC-HCV patients
were consecutively examined at our cen-
ter (none had been previously treated
with interferon). Diagnosis of HCV infec-
tion was based on abnormal serum amin-
otransferases levels of 6 months’
duration and positive testing for serum
anti-HCV markers and HCV-RNA, as pre-
viously reported (12). Liver biopsy was
performed (following clinical indication)
(10,12) in 403 patients. Patients with cir-
rhosis (by histology, laboratory evidence
of liver failure, and/or ultrasound-proven
portal hypertension) (10,12) or hepato-
cellular carcinoma were excluded.
Among 550 subjects randomly extracted
from the general registry of northwest
Tuscany and systematically screened for
thyroid disorders, 302 individuals 50
years of age were used as a population-
based age-matched control group. Sub-
jects with a history of alcohol abuse, drug
addiction, or positivity for markers of vi-
ral hepatitis were excluded. Furthermore,
82 patients 40 years of age with NC-
HBV (10) were consecutively screened.
Diagnosis of NC-HBV was based on ab-
normal serum aminotransferases levels
for 6 months and positive testing for
HBV-DNA, as previously reported (13).
Type 2 diabetes was diagnosed as a
fasting plasma glucose level7.0 mmol/l
on more than one occasion; subjects on
treatment with oral hypoglycemic agents
were also conisdered type 2 diabetic pa-
tients (10). Patients with type 1 diabetes
were excluded (10). In all study subjects,
fasting plasma glucose, cholesterol, tri-
glycerides, international normalized ra-
tio, and platelet counts were measured by
conventional methods (12). Written in-
formed consent was obtained from all
study subjects.
Data are given as means SD. Group
differences were analyzed by the 2 test or
relative risk (RR) for categorical variables
and two-way ANOVA for continuous
variables (with diabetes and HCV positiv-
ity as the factors).
RESULTS— As shown in Table 1, NC-
HCV patients, NC-HBV patients, and
control subjects were well matched for
sex and age. Mean international normal-
ized ratio (1.09 [range 0.83–1.29]) and
platelet counts (313,000/l [134,000–
436,000]) in the NC-HCV group were
not significantly different from those in
the NC-HBV (1.11 [0.81–1.32] and
306,000/l [128,000–443,000], respec-
tively) and control (1.06 [0.85–1.25] and
316,000/l [131,000–452,000], respec-
tively) groups.
The features specifically associated
with HCV were a lower BMI and re-
duced serum total and LDL cholesterol
concentrations. The prevalence of type 2
diabetes was significantly higher in NC-
HCV patients (12.6%) compared with
control subjects (7.0%) or NC-HBV pa-
tients (4.9%) (2  9.6, P 0.008). The
RR for type 2 diabetes in NC-HCV pa-
tients was 1.81 (95% CI 1.15–2.89) versus
control subject and 2.71 (1.08–7.07) ver-
sus NC-HBV patients. The clinical phe-
notype specifically associated with type 2
diabetes was characterized by slightly
older age; higher BMI, serum triglycer-
ides, and blood pressure levels; and lower
HDL cholesterol concentrations. More-
over, type 2 diabetic NC-HCV patients
had a significantly lower BMI than type 2
diabetic control subjects and a slightly but
significantly (P  0.05) higher BMI than
nondiabetic NC-HCV patients.
CONCLUSIONS— In the present
study, we found a large excess of type 2
diabetes (12.6%) among NC-HCV pa-
tients compared with a sample of the gen-
eral population or age-matched NC-
HBV subjects. The RR of type 2 diabetes
in NC-HCV was significantly higher
than in control subjects or NC-HBV pa-
tients. The present series is a case-control
study and not an epidemiological survey;
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however, the prevalence of type 2 diabe-
tes in control subjects (7%) was fully in
the range of the reported age-adjusted
prevalence rates for the Italian population
(4%) (10,14).
The current results closely agree with
those of the only population-based survey
to appear thus far in the literature (5),
which reported a threefold increased
odds ratio for type 2 diabetes in HCV
patients 40 years of age in the general
U.S. population. In that study, no distinc-
tion could be made between chronic hep-
atitis and cirrhosis because the clinical
status of the HCV patients was not as-
sessed. The prevalence of type 2 diabetes
found in our NC-HCV patients is similar
to that (17%) reported by Lecube et al. (9)
and to that (14%) reported for HCV-
related mixed cryoglobulinemia (12).
The current data suggest that HCV-
related hepatitis is associated with type 2
diabetes at a stage when liver function is
largely preserved. Interestingly, insulin
resistance in nondiabetic HCV occurs
already at an early stage in the course of
HCV infection (15).
Of further interest in our analysis is
the comparison between the clinical phe-
notype of hepatitic and diabetic patients.
Type 2 diabetes per se was associated with
older age, overweight, dyslipidemia, and
higher blood pressure levels, i.e., the
“metabolic syndrome” phenotype com-
monly seen in these patients. In contrast,
nondiabetic NC-HCV patients were lean
and had low LDL cholesterol levels. Low
LDL cholesterol levels have been linked
with HCV-induced hypobetalipoprotein-
emia as a consequence of a binding com-
petition between the virus and the hepatic
LDL receptor (16). Interestingly, our NC-
HCV with type 2 diabetes had an inter-
mediate clinical phenotype, as they were
significantly leaner (25.7 vs. 29.7 kg/m2)
and had lower LDL cholesterol concentra-
tions (3.2 vs. 3.6 mmol/l) than HCV-
negative diabetic patients (Table 1).
In conclusion, our study confirms an
association of type 2 diabetes with HCV-
related hepatitis and shows that HCV
diabetic patients have a different clinical
phenotype from classical type 2 diabetic
subjects. In fact, type 2 diabetic NC-
HCV patients present a significantly
lower BMI than diabetic control subjects
and a slightly but significantly higher BMI
than nondiabetic NC-HCV patients.
Further investigation is needed to as-
sess the biological basis for this associa-
tion and to test whether antiviral therapy
for HCV infection may prevent the ap-
pearance of type 2 diabetes.
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